Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA Carboplatin and Re-irradiation for Relapsing Glioblastoma
NCT03672721Phase 2Recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Jul 2018
- Primary completion
- Dec 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin in glioblastoma (GBM) (6 arms), sponsored by Université de Sherbrooke. Primary endpoints: Response on MRI using the RANO Criteria, Overall Survival and 1 more. Started Jul 2018; status: recruiting.
02
Drugs
carboplatin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03672721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672721.